TY - JOUR
T1 - Alterations to the protein profile of bladder carcinoma cell lines induced by plant extract MINA-05 in vitro
AU - Nguyen-Khuong, Terry
AU - White, Melanie Y.
AU - Hung, Tzong Tyng
AU - Seeto, Shona
AU - Thomas, Melissa L.
AU - Fitzgerald, Anna M.
AU - Martucci, Carlos E.
AU - Luk, Sharon
AU - Pang, Shiu Fu
AU - Russell, Pamela J.
AU - Walsh, Bradley J.
PY - 2009/4
Y1 - 2009/4
N2 - Bladder cancer (BLCa) is a severe urological cancer of both men and women that commonly recurs and once invasive, is difficult to treat. MINA-05 (CK Life Sciences Int'l, Hong Kong) is a derivative of complex botanical extracts, shown to reduce cellular proliferation of bladder and prostate carcinomas. We tested the effects of MINA-05 against human BLCa cell sublines, B8, B8-RSP-GCK, B8-RSP-LN and C3, from a transitional cell carcinoma, grade IV, to determine the molecular targets of treatment by observing the cellular protein profile. Cells were acclimatised for 48 h then treated for 72 h with concentrations of MINA-05 reflecting 1/2 IC50, IC50 and 2xIC50 (n = 3) or with vehicle, (0.5% DMSO). Dose-dependant changes in protein abundance were detected and characterised using 2-dimensional electrophoresis and MS. We identified 10 proteins that underwent changes in abundance, pI and/or molecular mass in response to treatment. MINA-05 was shown to influence proteins across numerous functional classes including cytoskeletal proteins, energy metabolism proteins, protein degradation proteins and tumour suppressors, suggesting a global impact on these cell lines. This study implies that the ability of MINA-05 to retard cellular proliferation is attributed to its ability to alter cell cycling, metabolism, protein degradation and the cancer cell environment.
AB - Bladder cancer (BLCa) is a severe urological cancer of both men and women that commonly recurs and once invasive, is difficult to treat. MINA-05 (CK Life Sciences Int'l, Hong Kong) is a derivative of complex botanical extracts, shown to reduce cellular proliferation of bladder and prostate carcinomas. We tested the effects of MINA-05 against human BLCa cell sublines, B8, B8-RSP-GCK, B8-RSP-LN and C3, from a transitional cell carcinoma, grade IV, to determine the molecular targets of treatment by observing the cellular protein profile. Cells were acclimatised for 48 h then treated for 72 h with concentrations of MINA-05 reflecting 1/2 IC50, IC50 and 2xIC50 (n = 3) or with vehicle, (0.5% DMSO). Dose-dependant changes in protein abundance were detected and characterised using 2-dimensional electrophoresis and MS. We identified 10 proteins that underwent changes in abundance, pI and/or molecular mass in response to treatment. MINA-05 was shown to influence proteins across numerous functional classes including cytoskeletal proteins, energy metabolism proteins, protein degradation proteins and tumour suppressors, suggesting a global impact on these cell lines. This study implies that the ability of MINA-05 to retard cellular proliferation is attributed to its ability to alter cell cycling, metabolism, protein degradation and the cancer cell environment.
UR - http://www.scopus.com/inward/record.url?scp=65349180762&partnerID=8YFLogxK
U2 - 10.1002/pmic.200700839
DO - 10.1002/pmic.200700839
M3 - Article
C2 - 19294694
AN - SCOPUS:65349180762
SN - 1615-9853
VL - 9
SP - 1883
EP - 1892
JO - Proteomics
JF - Proteomics
IS - 7
ER -